Clinical Trial Search

Primary: Percentage of Subjects Achieving a TNA Response of a Predefined Threshold Value at Day 63 (5 Weeks Following the Third Vaccination on Day 28). — 71.2; 68.5; 73.9; 76.7…

Primary: Overall Survival — 11.96; 10.78; 11.73; 10.87 Months — p=0.7428

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 85.8; 81.6 percentage of participants

Primary: Number of Participants Alive at Day 30 — 31; 39 Participants

Primary: Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of…

Primary: Percentage of Participants With Adverse Events — 78.3; 83.7 Percentage of participants

Primary: Adverse Experiences — 54 participants

Primary: The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups. — -0.04; -0.33 HbA1c…

Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAE's) — 5; 9 participants

Primary: Study Part 1- Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Per Dose — 14.30; 13.42 (IU·hr/dL) / (IU/kg)

Primary: Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL — 87; 35 participants

Primary: The Ratio of Total and Unbound DTG Concentrations Between Cerebrospinal Fluid (CSF) and Plasma at Week 2 and Week 16 — 0.516; 0.412 percentage

Primary: The Number of Subjects Who Reported Treatment-emergent Adverse Events (AE's) — 60; 59 participants

Primary: Change From Baseline in Worst Pain in the Past 24 Hours Assessed by Brief Pain Inventory (BPI) Short Form Questionnaire Score at Day 29 — 6.7; 6.9; -1.8; -1.8 Units on a…

Primary: Change From Baseline in Ocular Surface Disease Index© (OSDI) Score — 36.83; 38.51; 38.86; -14.72 Score on a scale